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ABSTRACT 
Patients with HF and their families experience stress and suffering from a variety of sources over 
the course of the HF experience. Palliative care is an interdisciplinary service and an overall 
approach to care that improves quality of life and alleviates suffering for those living with 
serious illness, regardless of prognosis. In this review, we synthesize the evidence from 
randomized clinical trials of palliative care interventions in HF. While the evidence base for 
palliative care in HF is promising, it is still in its infancy and requires additional high-quality, 
methodologically sound studies to clearly elucidate the role of palliative care for patients and 
families living with the burdens of HF. Yet, an increase in attention to primary palliative care 
(e.g., basic physical and emotional symptom management, advance care planning), provided by 
primary care and cardiology clinicians, may be a vehicle to address unmet palliative needs earlier 
and throughout the illness course.  
 
CONDENSED ABSTRACT 
Palliative care is the subspecialty, as well as the philosophy of care, focused on improving 
quality of life while relieving the symptoms and stress of serious illness. Although limited, 
evidence for palliative care in HF is promising and proliferating. Recognizing the complexities 
of prognostication in HF, palliative care need not be delayed in anticipation of trigger events, and 
should be delivered early and concomitant with HF therapies. Primary palliative care (e.g., 
physical and emotional symptom management, advance care planning) can initiated by 
cardiology or primary care clinicians, whereas patients with complex needs may be best served 
by specialty-level palliative care.  
 
Keywords: Palliative care, hospice, heart failure, quality of care, quality of life 
 
Abbreviations: ACCF, American College of Cardiology Foundation. AHA, American Heart 
Association. BTT, Bridge-to-transplant. CI, confidence interval. CMS, Centers for Medicare and 
Medicaid Services. DT, destination therapy. ED, emergency department. HF, heart failure. 
HFSA, Heart Failure Society of America. ICD, Implantable cardiac device. ISHLT, International 
Society for Heart and Lung Transplantation. QoL, quality of life. RCT, randomized clinical trial. 
TJC, The Joint Commission. VAD, ventricular assist device.  
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INTRODUCTION 
 Heart failure (HF) is a chronic, progressive, and ultimately lethal disease that affects 
more than 6 million American adults, with an additional 870,000 individuals diagnosed 
annually(1). Despite advances in HF therapies, nearly 40% of patients will die within a year of 
their first hospitalization(2). During the course of HF, patients typically experience debilitating 
physical and emotional symptoms, loss of independence, and disruptions to social roles, all of 
which severely degrade quality of life (QoL)(3,4). Physical symptoms in advanced HF, such as 
pain, are highly distressing for patients and caregivers, yet remain under-recognized and 
undertreated(5,6). Patients and their caregivers(7,8) often face decisions about high-risk and 
complex treatments (e.g., cardiac devices, transplantation) without adequate prognosis 
communication, decision support, or advance care planning(9,10).  In addition, HF management 
poses enormous financial and resource stress on families, healthcare systems, and society; direct 
medical costs of HF are projected to be more than $77 billion by 2030, a 215% increase from current 
spending(11). 
 Palliative care is an interdisciplinary approach, as well as a clinical subspecialty that 
focuses on improving QoL and reducing suffering among patients with serious illness and their 
families(12). Core domains of palliative care interventions include: expert assessment of pain 
and other physical symptoms, psychosocial care, identification of goals of care, and support for 
complex treatment and decision making. A recent systematic review and meta-analysis of 
palliative care interventions suggests that a palliative approach is associated with improved 
patient QoL, reduced symptom burden, and improved caregiver outcomes(13). However, most 
evidence for palliative care emanates from oncology; the role of palliative care in chronic, non-
malignant illnesses such as HF is underdeveloped(13).  
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 Palliative care takes many forms. Historically, a sub-specialty trained palliative care 
specialist works alongside patients’ primary clinicians to consult on or co-manage patients’ 
palliative needs. Alternatively, primary palliative care (or “basic” or “generalist” palliative care) 
is the concept that all clinicians, regardless of specialization, should be competent in 
fundamental palliative skills(14). These skills include basic physical and emotional symptom 
management, initial goals of care discussions, and patient referral to specialty palliative care or, 
for patients at the end of life, hospice care. Palliative care also varies by the location of service. 
More than 65% of U.S.  hospitals have a specialty palliative care program which delivers 
services to inpatients(15). Community- and outpatient-based palliative care models have been 
regarded as the “new frontier” in supporting patients and families longitudinally and across a 
variety of care settings(16).    
In this review, we describe the potential role of palliative care in improving outcomes in 
patients with HF, characterize typical palliative care delivery models and each model’s existing 
evidence, and describe future priorities for palliative care research and clinical practice models in 
HF. 
 
NATURAL OPPORTUNITIES TO INTEGRATE PALLIATIVE DOMAINS IN HF 
CARE 
Historically, the prevailing approach to palliative care has been one of a zero-sum game; 
palliative and curative therapies have been erroneously regarded as contradictory options(17). It 
is no longer appropriate to assume that palliative care should be initiated only as a treatment of 
last resort when traditional HF management fails to fulfill a patient’s goals. Particularly given the 
unpredictable trajectory of HF, waiting for a “trigger” event at which to initiate a palliative 
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approach – either primary palliative care or specialty palliative care consultation – perpetuates 
the false dichotomy of palliative versus (rather than palliative plus) life-prolonging therapy. In 
fact, there are often multiple natural opportunities to consider integrating various palliative 
domains throughout the HF trajectory (Central Illustration). For many patients, primary palliative 
care, such as basic symptom management and identifying a surrogate decision maker is provided 
by a primary care, cardiology, or HF clinician. Palliative care specialists can assist with the 
management of intractable symptoms, and more complex medical decision-making, such as 
instances of discordant patient-family goals or irresolvable unrealistic expectations of medical 
therapies. Recognizing the potential discordance between objective measures of disease severity 
(e.g., ejection fraction) and patient-reported outcomes (e.g., symptom burden, QoL), it is 
important that patient-reported outcomes, such as symptoms and QoL be monitored regularly 
throughout the entire HF experience by primary care and/or cardiology providers, so as to 
facilitate optimal patient-centered care. Ultimately, the optimal timing for integrating primary or 
specialty palliative care for patients with advanced HF will vary, reflecting patient need, not 
prognosis.  
 
Poorly controlled symptoms and psychosocial-spiritual distress 
Patients with HF often have a wide array of symptoms, including dyspnea, pain, anxiety, 
depression, sleep disturbance, and fatigue(18,19). There are varying levels of evidence for 
treating HF symptoms(20). Often, the ideal HF symptom management approach is treating the 
underlying HF condition (e.g., relieving dyspnea by addressing fluid overload); this is a clear 
example of the harmony between traditional HF disease management and a palliative 
approach(21). However, many symptoms persist despite optimal disease management. For 
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example, pain is common, yet under-recognized and therefore undertreated in HF(5). Similarly, 
depression occurs in an estimated 1 in 5 patients with HF, and is associated with worse QoL and 
increased mortality(22); yet routine screening for depression in HF is rare(23,24).  
The psychosocial-spiritual context of HF beyond depression and anxiety is 
understudied(25). The HF experience is rife with uncertainty, existential distress, and adjustment 
to modified social and professional roles. Additionally, patients considering advanced therapies 
such as VADs and cardiac transplantation face additional anxieties as they anticipate or adjusting 
to a new life post-receipt. In addition to limitations in personal roles, patients experience wide 
variability in social support and the availability of informal caregivers (e.g., friends, spouses, 
children)(26,27). Regarding spirituality, patients with HF and poor health status report worse 
spiritual well-being compared to patients with metastatic lung and pancreatic cancer(28).    
The assessment and treatment of physical symptoms and psychosocial-spiritual distress in 
HF should be the responsibility of patients’ ongoing care providers (i.e., primary care, 
cardiology, mental health) and community supports. Yet the assessment and treatment of HF 
symptoms need not wait until the point of intractability; palliative care principles should be 
integrated throughout the HF management continuum, allowing cardiology and primary care 
clinicians to serve as primary palliative care providers, alleviating symptoms before they become 
overly burdensome. Although the role of palliative care specialists is still being defined, if 
patient distress persists and palliative care specialists are available, referral should be considered. 
 
Hospitalization and Discharge 
Patients with HF have a higher rate of acute care service utilization in the 30 days before 
death than patients with cancer (ED visits: 64% vs. 39%, hospitalizations: 60% vs. 45%, and 
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ICU admissions: 19% vs. 7%)(29-34). Each hospital admission is an opportunity to discuss goals 
of care, as this is most likely when the treatment regimen for a patient with HF may escalate. As 
the risk for mortality increases with each subsequent hospitalization, hospital discharge planning 
is an opportunity to discuss what is most important, what QoL means to the patient/family, and 
under what circumstances they would and would not want life prolonging treatments(35). 
Furthermore, depending on the treatments initiated, the patient may require further assistance on 
discharge, such as home care, physical therapy, or cardiac rehabilitation.  In addition, many 
families are intimately involved in patient care. Caregivers suffer physical, psychological and 
financial consequences associated with this care(27). Therefore, clinicians should screen for 
caregiver burden and stress and help by providing support and counselling.  
 
End-of-Life Transition 
Although commonly conflated, palliative care and hospice are related but conceptually 
distinct services(17). Palliative care is both a clinical specialty, and an overall approach to care 
that focuses on improving QoL and relieving suffering for patients and families facing serious 
illness, based on need and not prognosis. Hospice care is a specific delivery mechanism of 
palliative care reserved for individuals at the end of life. In contrast to palliative care, hospice 
eligibility (in the U.S.) requires an estimated life expectancy of six months or less, and an 
agreement to forego life-sustaining procedures. One exception is the U.S. Veterans Health 
Administration, which allows for hospice care concurrent with life-sustaining treatments. 
Addressing a patient’s physical, psychosocial, and existential distress need not wait until the very 
end of life; palliative care should be seamlessly integrated throughout the HF experience, with 
referral to hospice services if and when its philosophy aligns with patient and family goals.   
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Patients with advanced HF (i.e., ACC/AHA stage D) have an estimated 1-year mortality 
of 29%, and an estimated 1-year freedom from hospitalization or death of only 32.9%(36). 
Despite this high morbidity and mortality, hospice utilization has remained low with about one-
third of patients with HF receiving hospice at time of death(37). Patients with advanced HF 
enroll in hospice at lower rates than those with cancer
19
 and compared to patients with cancer, 
patients with HF were more likely to enroll in hospice late in the course of their disease (within 
three days of death)(38). Nevertheless, numerous cardiology professional societies have called 
for the continued and earlier integration of hospice care for patients with advanced heart 
disease(39-43). Further training is needed to assist primary care and HF clinicians to identify 
patients who are eligible for hospice, to describe what hospice care can provide in different 
settings (i.e. home, inpatient and residence), and to introduce hospice as a treatment 
recommendation when appropriate. When conflict arises between patients and/or families or 
between clinicians about a hospice recommendation, specialty palliative care may be helpful in 
facilitating future treatment care planning.  
 
REVIEW OF RANDOMIZED CLINICAL TRIALS OF PALLIATIVE CARE IN HEART 
FAILURE 
Using a recently published systematic review of randomized clinical trials of palliative 
care interventions(13), we conducted a secondary analysis of studies that either exclusively 
enrolled patients with HF or reported results separately by disease group. Briefly, we searched 
MEDLINE, EMBASE CINAHL, and Cochrane Library’s CENTRAL, from database inception 
to July 22, 2016. Randomized clinical trials (RCTs) were eligible for inclusion if their 
interventions comprised at least two of the eight domains included in the definition of palliative 
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care from the National Consensus Project for Quality Palliative Care(44). Two investigators 
independently screened and reviewed the resulting 6,158 unique records, ultimately yielding 43 
trials; of these 43, five trials either only included patients with HF or presented data by disease 
group, and were therefore eligible for inclusion. One relevant additional trial was hand selected 
as it was published after our initial search(45). Each study was evaluated for risk of bias for 
subjective outcomes (e.g., patient-reported outcomes) and objective outcomes (e.g., survival, 
resource utilization) using the Cochrane Risk of Bias tool(46). A complete description of the 
search and analytic methodology is available elsewhere(13). Although this search is restricted to 
six studies of the strongest methodological design (i.e., RCTs), it should be noted that some 
quasi-experimental and observational studies have demonstrated potential benefits of palliative 
care interventions in HF patients(47-50).  
 
Inpatient Specialty Consultation or Co-management  
Two RCTs of inpatient specialty team-based consultation yielded mixed results about the 
impact of palliative care on healthcare utilization, yet provide some evidence for potential 
benefits of palliative care on patient-level outcomes (Table 1). However, because both trials were 
deemed to be at high risk of bias results should be interpreted cautiously.  
A 2015 trial compared the impact of inpatient consultation by a palliative care team 
versus usual care for patients hospitalized for acute HF(51). The authors reported statistically 
significant improvements for all patient-reported outcomes measured, including QoL, symptom 
burden, and mood. There was no effect on patient survival. Although the intervention was 
associated with increased advance care planning, no effect was found regarding 30-day hospital 
readmission, nor on hospice referral. Strengths of this study included the use of a multi-
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professional team approach similar to the ideal model of palliative care delivery in inpatient 
settings (i.e. palliative care physicians, advance practice nurses, social workers, and chaplains). 
However, given that patients in the trial were financially responsible for any subsequent 
palliative care visits, the majority of patients (80%) received only one visit which does not allow 
comment on the effects of a more longitudinal palliative approach. 
Hopp and colleagues evaluated the effect of inpatient palliative care consultation within 
three urban U.S. hospitals (n=85). Intervention content included symptom assessment and 
management, elicitation of goals of care, advance care planning, and discharge planning(52). No 
effect was found regarding the trial’s composite primary outcome at 3-6-month follow-up of 
hospice utilization or the creation of a “do not resuscitate” order during or after the index 
hospitalization (difference, 9.3%), but with wide confidence intervals (95% CI −11.8% to 30.0%; 
p = 0.12). No statistically significant effect was found regarding patient survival (p=0.47).  
 
Outpatient Specialty Palliative Care 
 The most compelling evidence of the benefits of palliative care in HF arguably comes 
from the recently published PAL-HF (Palliative Care in Heart Failure) study (low risk of bias; 
Table 2) (45). This trial randomized 150 recently hospitalized individuals with advanced HF at 
high risk of re-hospitalization or six-month mortality to either usual care or usual care plus a six-
month interdisciplinary palliative care intervention led by a palliative care-specialized nurse 
practitioner. The protocolized intervention aimed to improve patient QoL by addressing physical 
and emotional symptoms, spiritual concerns, and advance care planning. Compared to usual care, 
the palliative care intervention was associated with clinically significant improvements in HF-
 12 
specific and disease-generic QoL at six-month follow-up (mean difference on KCCQ, 9.49 
points; 95% CI: 0.94, 18.05; mean difference on FACIT-Pal, 11.77 points; 95% CI: 0.84, 22.71). 
The trial also reported statistically significant improvements in secondary outcomes such as 
mood, and spiritual wellbeing. The intervention was not found to be associated with mortality or 
re-hospitalization.  
 
Home-Based Specialty Palliative Care 
Two RCTs of home-based palliative care interventions enrolled individuals with 
advanced disease (NYHA class III-IV) and provided palliative content embedded within a larger 
framework of disease management, including care coordination and a multidisciplinary team 
approach (Table 3)(53,54). Although results are generally promising, both trials were deemed to 
be at high risk of bias; therefore, findings should be cautiously interpreted(13).  
Brännström and colleagues conducted a trial of a home-based integrated HF disease 
management and palliative care intervention delivered by a multidisciplinary team(54). 
Compared to usual care, patients who received the palliative care intervention reported 
statistically significant improvements in QoL at six weeks, despite no effect on symptom burden. 
The intervention was associated with fewer hospitalizations over six months (mean 0.42 vs 1.47, 
p=0.009), while there was no association identified regarding total costs of care. In addition, a 
greater proportion of patients in the intervention group experienced improvement in NYHA 
functional class at six months (39% vs. 9%, p=0.015).   
In a trial of transitional palliative care, Wong and colleagues randomized 84 patients 
recently discharged from the hospital to receive a combination of home visits and telephone 
check-ins from palliative care home nurses, or an attention control (i.e., social phone calls 
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regarding unrelated topics) (53). At twelve-week follow-up, intervention patients had 
significantly fewer hospital readmissions than control patients (relative risk (95% CI), 0.55 (0.35, 
0.88)), and higher satisfaction with their healthcare. At 12 weeks, the intervention was also 
associated with reduced symptom burden, and improved QoL.  
 
Primary Palliative Care 
We identified one RCT of a primary palliative care intervention for patients with HF 
(unclear risk of bias due to potential concerns regarding intervention fidelity; Table 4). Within 
four Veterans Affairs Medical Centers, Bekelman and colleagues compared the effectiveness of 
a collaborative care management and telemonitoring intervention versus usual care(55). At one-
year follow-up, there was no significant difference between groups regarding QoL (primary 
outcome). Among secondary outcomes, there was no difference in rates of hospital readmission 
(29.4% vs. 29.9%, p=0.87). Although one-year mortality was decreased among the intervention 
group (4.3% vs. 9.6%, p=0.04), this finding should be viewed as preliminary given that it was a 
secondary outcome.  
 
Summary of evidence 
Six palliative care intervention trials met inclusion criteria. Although the evidence base 
for palliative care in HF is nascent, there is somewhat consistent evidence that a palliative 
approach improves a variety of patient-centered outcomes, including symptom burden and QoL. 
Nevertheless, it is clear that research regarding palliative care in HF is still developing, and due 
to concerns regarding risk of bias in the majority of included trials, conclusions should be 
interpreted cautiously.  Yet, recent evidence from the high-quality PAL-HF trial provides support 
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for the notion that longitudinal palliative care, provided concomitantly with usual HF 
management, is associated with improved patient-centered outcomes(45).  
 
EXISTING CLINICAL GUIDELINES REGARDING PALLIATIVE CARE IN HF 
There are growing numbers of guidelines from major cardiology societies, including the 
American College of Cardiology Foundation (ACCF), American Heart Association (AHA), 
International Society for Heart and Lung Transplantation (ISHLT), the Heart Rhythm Society, 
and Heart Failure Society of America (HFSA), encouraging the incorporation of palliative care 
into the care of patients with HF. Historically, most of these guidelines have focused on end-of-
life decision making with respect to device management, including implantable cardiac 
defibrillators (ICD) and mechanical circulatory support, or referral to hospice. More recently, 
there has been an acknowledgement of the benefits of palliative care earlier in the disease 
trajectory(39).  
Several guidelines also advocate that the HF and specialty palliative care teams jointly 
help patients and families decide on treatment options, with an emphasis on decision-making in 
the context of advanced HF. For example, the 2013 ISHLT statement recommended that 
specialty palliative care consultation should be included in the treatment of end-stage HF during 
the evaluation phase for mechanical circulatory support, and that in addition to managing 
symptoms, clinicians should be having discussions about goals and preferences for end-of-life 
care with patients receiving mechanical circulatory support as destination therapy(41). In 2012, 
AHA experts recommended referral to specialty palliative care for assistance with difficult 
decision making, symptom management in advanced disease, and caregiver support, 
emphasizing that “the use of palliative care services should not be considered equivalent to the 
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withdrawal of disease-modifying therapies.”(40) A 2015 HFSA statement also recommended 
incorporating specialty palliative and hospice care into patients with advanced HF care plans, 
specifying that decision making should include the patient’s wishes for survival improvement 
versus QoL optimization(42).  
The above recommendations have recently expanded into The Joint Commission (TJC) 
and the Centers for Medicare & Medicaid Services (CMS) mandates. As of October 30, 2014, 
TJC revised its requirements for disease-specific advanced certification program for Ventricular 
Assist Device (VAD) for Destination Therapy (DT)(56) and specifically added a requirement to 
include a specialty palliative care representative to the core interdisciplinary team. Following 
TJC updates, CMS published its final memorandum for VADs for Bridge-to-Transplant (BTT) 
and DT, again mandating the inclusion of palliative care specialists in the multidisciplinary team 
of medical professionals caring for beneficiaries receiving VADs as DT(57).  
As illustrated, multiple guidelines advocate for the involvement of specialty palliative 
care in decisions regarding high-technology interventions and end-of-life care. However, there is 
little emphasis on (1) addressing the many domains of patient and family QoL aside from 
functional status, (2) integrating palliative care earlier in the HF trajectory, or (3) providing 
palliative care concurrently with HF-directed therapies, particularly for patients who are 
ineligible for or who prefer not to receive cardiac devices.   
 
PRIORITIES FOR FUTURE RESEARCH AND CLINICAL IMPLEMENTATION OF 
PALLIATIVE CARE IN HF 
 To date, the rationale for palliative care in HF has largely been one of analogy from the 
benefits reported from studies of palliative care in oncology. Yet, it is neither likely nor 
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appropriate to assume that the framework of palliative care used in oncology is optimal for 
patients living with chronic, non-malignant illnesses, such as HF. Indeed, the next era of 
palliative care research and clinical implementation will challenge the status quo of palliative 
care, both in terms of content and structure, to maximize impact and uptake in chronic 
illness.(58) Whereas few randomized trials of palliative care interventions exist in HF, as we 
have illustrated, these trials are an important yet imperfect starting point for future investigation. 
Three critical questions remain unanswered in the literature representing the next priorities in 
explicating the role of palliative care in HF.  
First, how do we build capacity in addressing the unmet palliative needs of patients with 
HF? True innovation regarding the ability to disseminate and sustain palliative care will disrupt 
the prevailing reliance on the increasingly scarce resource of palliative care specialists(59). 
Indeed, all clinicians caring for patients with serious illness, like HF, should possess a 
fundamental palliative proficiency to alleviate suffering (e.g., basic management of physical and 
psychological symptoms, eliciting goals of care, responding to family concerns)(14). Initial 
efforts to educate cardiology fellows in palliative care competencies, such as communication, are 
underway(60,61). Research is needed to understand how to improve education regarding primary 
palliative care domains that are relevant to patients with advanced HF, such as elicitation of 
goals of care, advance care planning, and caregiver support. As a result, not only is palliative 
care normalized, it is also able to be provided seamlessly and longitudinally across the HF 
experience – not solely in the inpatient setting in response to acute decompensation crises. 
Indeed, multiple aspects of palliative care (e.g., symptom self-management, care coordination, decision 
support, patient activation) align with principles of disease management and HF self-care(62,63).  For 
example, primary clinicians should provide proactive education and support to patients to promote self-
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management of burdensome symptoms, while offering specialty palliative care resources as an option 
if these needs become intractable. Furthermore, for patients without complex palliative concerns, it may 
be unnecessary to involve a palliative care specialist, which could further fragment care(14). We 
present suggested roles for primary and specialty palliative care in HF in Table 5. Yet these 
considerations for primary palliative care in HF are largely theoretical(58); research is needed to 
examine integrating primary palliative care within primary care and cardiology settings, 
reserving specialty palliative care for patients with complex needs. 
Second, which palliative care models and delivery methods are most effective in 
optimizing outcomes for a particular patient with HF? Trials are needed to identify the 
comparative effectiveness of various permutations of palliative care delivery in HF, specifically 
across two characteristics: provider specialization (e.g., primary care vs. cardiology vs. palliative 
care) and delivery method (e.g., in person vs. telephonic vs. video-based). First, although more 
studies are needed to confirm the effectiveness of primary palliative care in HF, subsequent trials 
must directly compare this model with specialty palliative care management. Whereas intuition 
would argue for the relative superiority of specialty palliative care over a primary palliative 
approach, this assumption remains untested, and, as noted previously, access to specialty care for 
all HF patients is considerably limited. Second, while evidence suggests that telephone-based 
palliative care is effective in oncology(64), no head-to-head trial has evaluated this model against 
in-person palliative care. It is unclear whether palliative care delivered remotely is equivalent to 
the arguably more resource-intensive method of in-person consultation. To ensure maximal 
relevance, these studies must simultaneously assess patient (e.g., QoL, symptom burden), 
caregiver (e.g., burden, mood), and health system outcomes (e.g., utilization, costs).  
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Third, which treatments are most effective for addressing symptom burden in patients 
with HF? Although the most common symptoms for patients with HF are well known to be 
depression, anxiety, sleep disturbance, fatigue, dyspnea, and pain(48,65,66), additional studies 
are needed to expand the range of effective treatment modalities for these symptoms. For 
example, recent intervention studies of psychiatric comorbidity in HF have failed to yield a clear 
conclusion of the effectiveness of treatments(67). This is likely due to differences in the 
underlying pathophysiology of these symptoms, which may differ in cardiac versus non-cardiac 
conditions(68,69). Given this gap in the literature, it remains challenging to effectively treat 
these very burdensome symptoms. Furthermore, due to often extreme medical complexity and 
frailty in this population, it can often be additionally difficult to discern a distinct symptom from 
progression of the overall disease process (e.g. fatigue due to depression or due to HF). 
Relatedly, the severity of perceived symptoms notoriously reflects poorly the degree of 
underlying cardiac pathophysiology. For example, dyspnea is experienced in up to 90% of 
patients with HF(70), yet this is frequently in the absence of hypoxemia or hypercapnia(71). In 
addition, physiological measures of disease severity, such as ejection fraction, may be inadequate 
proxies for health status and other subjective markers of well-being(72). Idiosyncrasies such as 
these further complicate studies of potential palliative treatments due to the difficulty of 
establishing appropriate subject inclusion and response criteria for these symptoms. 
 
CONCLUSION 
Although the evidence base for palliative care in HF is in its infancy(73,74), interest in 
this area continues to proliferate as evidenced by the recent publication of the groundbreaking 
PAL-HF trial, as well as multiple clinical trials also underway examining various forms of 
 19 
palliative care delivery in HF. Given the growing prevalence of HF, the integration of palliative 
care within HF management represents an opportunity to affect the public health issue of poor 
QoL in patients and caregivers, while also optimizing care delivery. Furthermore, research and 
clinical implementation of palliative care in HF can serve as a vanguard for explicating the role 
of palliative care in other chronic, non-malignant illnesses.  
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FIGURE TITLES AND LEGENDS 
Central Illustration. Integrating Palliative Care Across the Heart Failure Experience 
Legend: Core domains of primary palliative care (e.g., symptom assessment and management, 
psychosocial support, advance care planning) may be seamlessly integrated within usual HF 
disease and device management. When appropriate, specialty palliative care services may be 
initiated to address complex or intractable palliative needs. The timing of these referrals should 
be based on patient need, not prognosis, and can be initiated at any point during the HF 
trajectory. Stars depict key events, such as acute decompensation or hospitalization, that may be 
particularly salient opportunities for evaluation of appropriateness for specialty palliative care 
referral or hospice referral, if aligned with a patient’s goals. Given that symptoms, functional 
status, and QoL are not perfectly correlated, it is important that palliative needs such as 
symptoms and QoL be routinely and systematically monitored throughout the patient’s HF care 
trajectory.   
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Table 1. Summary of Existing Trials of Inpatient Specialty Palliative Care in Heart Failure 
Study 
(Country) 
Patient 
Population* 
Intervention 
(Participants 
Randomized) 
Control 
(Participants 
Randomized) 
Results Risk of Bias 
Subjective Objective 
Hopp et al, 
2016 
(USA) 
Acute HF, 
1-yr 
mortality 
risk of 
≥33%, 
and/or 
NYHA 
Class III-IV  
(Mean age: 
68) 
Inpatient 
specialist 
consultation 
from a 
multidisciplinary 
team (physician, 
nurse 
practitioner, 
chaplain, social 
worker) 
conducted 
clinical 
interview(s), 
assessing 
symptoms, goals 
of care and post-
treatment 
location desires, 
and advance 
Usual care 
(n=42) 
Hospice 
utilization/ACP 
(Composite 
outcome): NS; 
difference 
between groups 
9.3% (95% CI: -
11.8%, 30.0%) 
High High 
 27 
care planning 
(n=43) 
Sidebottom 
et al, 2014 
(USA) 
Acute HF  
(Mean age: 
73) 
Specialty 
multidisciplinary 
palliative care 
consultation 
assessing 
physical and 
emotional 
symptoms, 
spiritual, and 
social aspects of 
care. (n=116) 
Usual care 
(n=116) 
QOL 
[Minnesota 
Living with 
Heart Failure 
Questionnaire]: 
Improved, mean 
difference 3.06 
points (95% CI: 
2.75, 3.37)  
Symptom 
burden 
[ESAS]: 
Improved total 
symptom 
burden, mean 
difference 4.31 
points (95% CI: 
4.00, 4.62) 
Six-month 
mortality: NS; 
High High 
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HR, 1.90 (95% 
CI: 0.88, 4.09) 
30-day hospital 
readmission: 
NS; HR, 1.43 
(95% CI: 0.5, 
4.1) 
Hospice use 
within 6 
months: NS; 
HR, 1.60 (95% 
CI: 0.58, 4.38) 
ACP within 6 
months: 
Improved; HR, 
2.87 (95% CI: 
1.09, 7.59) 
Mood [PHQ-9]: 
Improved; mean 
difference, 0.72 
(95% CI: 0.41, 
1.03) 
 29 
ACP=Advance Care Planning. CI=Confidence Interval. ESAS= Edmonton Symptom 
Assessment Scale. HF=Heart Failure. NS=Not significant. NYHA=New York Heart Association. 
PHQ-9= Patient Health Questionnaire 9. QOL=Quality of Life. USA=United States of America. 
* Patient population details the indication for palliative care. All comparisons stated as 
intervention vs. control.  
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Table 2. Summary of Existing Trials of Outpatient Specialty Palliative Care in Heart Failure  
Study 
(Country) 
Patient 
Population* 
Intervention 
(Participants 
Randomized) 
Control 
(Participants 
Randomized) 
Results Risk of Bias 
Subjective Objective 
Rogers et 
al, 2017 
(USA) 
Hospitalization 
for HF in past 
year and 
ESCAPE score 
>=4 indicating 
>50% risk of 
6-mo. 
mortality. 
(Mean age: 71) 
Interdisciplinary NP-led 
specialty palliative care 
intervention concomitant 
with usual HF 
management. Intervention 
foci included: physical 
and emotional symptom 
management, spiritual 
concerns, and advance 
care planning. (n=75) 
Usual care 
(n=75) 
QOL [KCCQ]: 
Improved at 6 
months, mean 
difference 9.49 
points (95% CI: 
0.94, 18.05; 
p=0.03) 
[FACIT-Pal]: 
Improved at 
6 months, mean 
difference 11.77 
points (95% CI: 
0.84, 22.71; 
p=0.035) 
Mood  
[HADS 
depression]: 
Improved at 6 
months, mean 
Low Low 
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difference -1.94 
points (95% CI: 
3.57, -0.31; 
p=0.02) 
[HADS 
anxiety]: Improved 
at 6 months, mean 
difference -1.83 
points (95% CI: -
3.64, -0.02; 
p=0.048) 
Spiritual 
wellbeing 
[FACIT-Sp]: 
Improved @ 6 
months, mean 
difference 3.98 
points (95% CI: 
0.46, 7.50; 
p=0.027) 
6-month 
mortality: NS, 
30.7% vs 26.7% (p 
 32 
value not 
reported).  
HF-related 
Rehospitalization: 
NS, 30.7% vs. 
29.3% (p value not 
reported) 
CI=Confidence Interval. ESCAPE=Evaluation Study of Congestive Heart Failure and Pulmonary 
Artery Catheterization Effectiveness. FACIT-Pal=Functional Assessment of Chronic Illness 
Therapy - Palliative care. FACIT-Sp=Functional Assessment of Chronic Illness Therapy - 
Spiritual Well-Being. HADS= Hospital Anxiety and Depression Scale. HF=Heart Failure. 
KCCQ=Kansas City Cardiomyopathy Questionnaire. NP=Nurse Practitioner. NS=Not 
significant. QOL=Quality of Life. USA=United States of America. * Patient population details 
the indication for palliative care. All comparisons stated as intervention vs. control. 
  
 33 
Table 3. Summary of Existing Trials of Home-Based Specialty Palliative Care in Heart Failure 
Study 
(Country) 
Patient 
Population* 
Intervention 
(Participants 
Randomized) 
Control 
(Participants 
Randomized) 
Results Risk of Bias 
Subjective Objective 
Brännström 
et al, 2014 
(Sweden) 
NYHA 
Class III-IV 
HF 
(Mean age: 
79) 
Predominately 
in-home HF 
disease 
management and 
palliative care 
services via a 
multidisciplinary 
approach and 
care 
coordination 
(n=36) 
Usual care 
(n=36) 
QOL [EQ5D]: 
Improved; (57.6 
± 19.2 vs. 48.5 ± 
24.4; P=0.05) 
 [KCCQ]: NS 
(data not 
reported) 
Symptom 
burden [ESAS]: 
NS (data not 
reported) 
Six-month 
survival: NS; 
P=0.34 
Hospitalizations: 
reduced; mean 
(SD)=0.42 (0.60) 
vs. 1.47 (1.81); 
P=0.009 
High High 
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Total costs: NS; 
mean €4078 vs. 
€5727 (P not 
reported) 
Increased 
proportion of 
patients with 
improved 
NYHA class 
(39% vs. 9%; 
P=0.015) 
Wong et al, 
2016 
(Hong 
Kong) 
Advanced 
HF (e.g. 
NYHA 
stage III-IV) 
(Mean age: 
78) 
Palliative care 
home nurses 
conducted home 
visits/telephone 
calls providing 
transitional 
palliative care 
(n=43) 
Usual care 
(n=41) 
Symptom 
burden [ESAS]: 
Proportion of 
patients with 
improvement in 
total score, 73% 
vs. 41.4%, 
P<0.05 
QOL [McGill]: 
Improved at 4 
weeks; 7.57 
points vs. 6.46 
High High 
 35 
points; P<0.001 
[Chronic HF 
Questionnaire]: 
Improved at 4 
weeks; 5.26 
points vs. 4.47 
points; P<0.001 
Satisfaction with 
care: Higher at 4 
weeks; 48.84 
points vs. 3.55 
points, P<0.001 
Hospital 
readmission: NS 
at 4 weeks; 
20.9% vs. 29.3%, 
P=0.38; Reduced 
at 12 weeks: 
33.6% vs. 61%, 
P=0.009 
ACP=Advance Care Planning. ESAS= Edmonton Symptom Assessment Scale. EQ5D= EuroQol 
Five Dimensions Questionnaire. HF=Heart Failure. KCCQ= Kansas City Cardiomyopathy 
Questionnaire. NS=Not significant. NYHA=New York Heart Association. QOL=Quality of Life. 
 36 
SD=Standard deviation. USA=United States of America. * Patient population details the 
indication for palliative care. All comparisons stated as intervention vs. control.  
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Table 4. Summary of Existing Trials of Primary Palliative Care/Collaborative Care Models in 
Heart Failure 
Study 
(Country) 
Patient 
Population* 
Intervention 
(Participants 
Randomized) 
Control 
(Participants 
Randomized) 
Results Risk of Bias 
Subjective Objective 
Bekelman 
et al, 2015 
(USA) 
HF with 
poor QOL, 
limited 
functional 
status, and 
significant 
symptoms 
(KCCQ 
score <60) 
(Mean age: 
68) 
Multidisciplinary 
collaborative HF 
disease 
management, 
and tele-
monitoring with 
patient self-care 
support (n=187) 
Usual care 
(n=197) 
QOL 
[KCCQ]: NS 
at 1 year; 
54.2 (95% 
CI, 51.7 to 
56.6) vs. 
53.6 (95% 
CI, 51.1 to 
56.0) 
Mortality: 
Decreased at 
1 year; 4.3% 
vs. 9.67%, 
P=0.04 
Mood [PHQ-
9]: 
Improvement 
in depression 
Unclear Unclear 
 38 
among 
patients with 
initial 
positive 
screen; mean 
difference, 
2.1-point 
reduction 
(95% CI, 
0.43 to 3.78); 
P=0.01 
Hospital 
readmission: 
NS at 1 year; 
29.4% vs. 
29.9%; 
P=0.87 
HF= Heart Failure. KCCQ= Kansas City Cardiomyopathy Questionnaire. NS=Not significant. 
PHQ-9= Patient Health Questionnaire 9. QOL=Quality of Life. USA=United States of America. 
* Patient population details the indication for palliative care. All comparisons stated as 
intervention vs. control. 
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Table 5. Primary palliative care versus specialist palliative care for patients with HF and 
their families 
Domain Primary Palliative Care 
(PPC) 
When to refer to specialist 
palliative care (SPC) 
Symptom 
Management 
Shortness of Breath  Maximize HF 
therapies to relieve 
congestion 
 Debilitating refractory 
dyspnea despite PPC 
interventions 
Pain  Determine etiology of 
pain and treat 
accordingly 
 Maximize antianginal 
medications and 
recommend activity 
modification for 
anginal pain 
 Refer to physical 
therapy, if appropriate 
 Refer to 
multidisciplinary pain 
teams and pain 
specialists, if 
appropriate 
 Pain refractory to PPC 
interventions 
Depressed Mood  Distinguish adjustment  Symptoms of major 
 40 
disorder from 
depressive disorder 
 Treat adjustment 
disorder with 
supportive counseling 
or referral for 
psychotherapy   
 Treat depressive 
disorder with referral 
to cognitive-behavioral 
therapy and consider 
medication 
management; consider 
referral to 
psychiatrist/psychologi
st 
depressive disorder 
such as incapacitating 
hopelessness, 
anhedonia, or 
suicidality requiring 
medical management 
Anxiety  Treat mild anxiety 
with referral to 
psychologist for help 
with relaxation 
techniques and 
psychotherapy or 
initiation of anxiolytic 
 Debilitating anxiety or 
panic symptoms that 
develop at the time of 
or shortly after HF 
diagnosis that prevent 
patient from 
participating in regular 
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medication (if 
appropriate) 
 Refer to psychiatrist 
for severe anxiety 
activities 
Nausea  Adjust HF therapies 
 Determine etiology of 
nausea (e.g., 
gastroparesis vs. 
supratherapeutic drug 
levels or electrolyte 
abnormalities) 
 Ongoing symptoms 
despite PPC 
interventions 
 
Fatigue  Optimize HF therapies 
 Refer to cardiac 
rehabilitation 
 Evaluate and treat for 
insomnia 
 Evaluate for sleep 
disordered breathing, 
if indicated 
 Ongoing symptoms 
despite PPC 
interventions 
Insomnia  Educate on sleep 
hygiene 
 Educate on relaxation 
techniques 
 Ongoing symptoms 
despite PPC 
interventions 
 42 
 Refer for cognitive-
behavioral therapy 
Communication 
and Advance 
Care Planning 
Discussing code 
status 
 Basic education and 
discussions about 
implications of CPR 
 Patients with 
misunderstandings of 
illness and prognosis 
after CPR 
Advance care 
planning, including 
decisions to 
withdraw life-
sustaining therapies 
 Engage patient and 
family in discussions 
to elicit goals of care 
and identify surrogate 
 Identify preferences 
regarding cardiac 
device deactivation (if 
appropriate) 
 Patients with 
misunderstandings of 
their illness and 
prognosis 
 Patients and families 
who are in 
disagreement about the 
patient’s end-of-life 
choices 
 Patient or family are in 
disagreement about the 
chosen surrogate or if 
patient is ambivalent 
about choice 
 Patients and/or 
surrogates who are in 
disagreement about the 
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treatment that best 
matches patient’s goals 
and values 
 Surrogates who lack 
insight into patient’s 
goals and values 
LVAD 
Preparedness 
Planning/Transplant 
Decisions 
 Involve palliative care 
specialist (per TJC 
recommendations) 
 SPC can review 
treatment options with 
patient 
Request for assisted 
suicide 
 Refer to specialist 
level palliative care or 
ethics consultation 
 SPC to navigate 
complex request and 
explore other options 
Psychological 
support 
Patient support  Supportive listening 
 Refer to social work or 
community resources 
(if available) 
 Refer to SPC when 
needs exceed the 
expertise of HF social 
worker, especially 
around issues of end-
of-life care, such as 
counseling parents on 
how to talk with their 
children 
Caregiver support  Supportive listening  Patient’s needs exceed 
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 Refer to social work or 
community resources 
(if available) 
the expertise of the HF 
social worker, 
especially if caregiver 
has significant needs 
or the patient and 
caregiver are in 
conflict 
Care 
Coordination 
 
 
 
 
 Communicate with 
other healthcare 
providers 
 Refer for home 
hospice for patients 
with good support at 
home and without 
complex medical or 
social needs 
 Complex hospice or 
home care referral for 
patients who require 
placement in facilities 
with need for complex 
medical management 
(e.g., palliative home 
inotropes) 
Adapted with permission from: Gelfman, L.P., Kavalieratos, D., Teuteberg, W.G. et al. Heart 
Fail Rev (2017). doi:10.1007/s10741-017-9604-9 
Abbreviations: HF, heart failure. PPC, primary palliative care. SPC, specialty palliative care. 
LVAD, left ventricular assist device. TJC, The Joint Commission. CPR, cardiopulmonary 
resuscitation. 
 
